Full-Time

Medical Science Liaison

Inflammation

Posted on 9/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$157k - $212.4k/yr

Indianapolis, IN, USA + 8 more

More locations: Richmond, IN, USA | Detroit, MI, USA | Greenwood, IN, USA | Fishers, IN, USA | Flint, MI, USA | Columbus, IN, USA | Lansing, MI, USA | Bloomington, IN, USA

Remote

Field-based role requiring 60–70% travel across the Indiana and Michigan territory.

Bachelor's, Master's, PharmD, PhD, MD

Category
Biology & Biotech
Required Skills
Veeva
CRM

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree, or a master's degree with 3 years of Medical Affairs experience, or a bachelor's degree with 5 years of Medical Affairs experience.
  • A current ability to communicate accurate, balanced, and scientifically rigorous medical and scientific information.
  • The ability to build and maintain strong relationships with external stakeholders and effectively communicate scientific data.
Responsibilities
  • Engage in peer-to-peer activities with Respiratory, Gastroenterology, and conditions related to product indication expansion, interacting with Opinion Leaders, community healthcare providers, and Population Health Decision Makers.
  • Travel 60–70% for territory management and provider engagement, and attend national and regional conferences, workshops, and company meetings.
  • Engage with clinical investigators and sites in support of the therapeutic area pipeline when indicated.
  • Engage with Population Health Decision Makers within territory health systems and clinics to communicate scientific, clinical-outcomes, and economic data.
  • Connect external and internal stakeholders to amplify Amgen's reach and patient access.
  • Conduct in-depth scientific exchange consistent with Medical Science Liaison compliance standards.
  • Support Amgen-sponsored research and serve as a study lead when assigned.
  • Liaise with potential investigators in non-sponsored clinical research.
  • Present field observations and insights to internal stakeholders to inform Amgen strategies.
  • Lead and support congress activities as aligned with strategy.
  • Support speaker training and ensure speakers are updated on new data.
  • Lead or participate on project teams supporting Medical Science Liaison strategies and tactics as delegated by Medical Science Liaison leadership.
  • Partner compliantly across Amgen field roles that share customers to create a coordinated customer experience.
  • Execute administrative responsibilities and training, including Veeva/ALIGN customer relationship management, expense reports, and compliance modules.
  • Maintain and improve clinical and scientific expertise using current data, information, and healthcare trends.
Desired Qualifications
  • A Pharm.D., Ph.D., M.D., or D.O.; other doctoral degrees are also considered.
  • At least 1 year of Medical Affairs experience.
  • At least 4 years in a medically related field, including 1 year focused on clinical practice, clinical research, or medical research; post-doctoral training such as residencies or fellowships may count.
  • Current Scientific Affairs or Medical Affairs experience at a biotechnology or pharmaceutical company.
  • Respiratory, Gastroenterology, or Inflammation expertise.
  • Experience with the designated territory.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.